• BSE
  • NSE
    • {{d.cmpname}}
    • {{d.price}}
    • ({{d.PerChg}}%)
Equity | News | Hot Pursuit
Hot Pursuit
Aurobindo Pharma gains after launching drug in US
(10:43, 11 Jul 2019)

The announcement was made after market hours yesterday, 10 July 2019.

Meanwhile, the S&P BSE Sensex was up by 165.93 points, or 0.43% to 38,722.97.

On the BSE, 1.14 lakh shares were traded in the counter so far compared with average daily volumes of 1.06 lakh shares in the past two weeks. The stock had hit a high of Rs 621.70 and a low of Rs 602.90 so far during the day. It hit a 52-week high of Rs 838 on 30 April 2019 and a 52-week low of Rs 566 on 19 July 2018.

Aurobindo Pharma announced the launch of Cinacalcet Hydrochloride tablets (30mg, 60mg and 90mg) in the US market in accordance with the terms of settlement agreement with Amgen Inc. The drug is a generic version of Amgen Inc's Sensipar tablets. Cinacalcet Hydrochloride tablets had an annual sale of approximately $1,449 million for the twelve months ending May 2019 as per IQVIA.

The drug is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKO) on dialysis; hypercalcemia in adult patients with parathyroid carcinoma; and severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy.

On a consolidated basis, Aurobindo Pharma's net profit rose 15.7% to Rs 611.32 crore on a 30.4% rise in the net sales to Rs 5201.98 crore in Q4 March 2019 over Q4 March 2018.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Powered by Capital Market - Live News

DB (International) Stock Brokers Limited: SEBI Reg. No.-INZ000179035 / CDSL : IN-DP-CDSL-266-2004 MCX-SX:INE 260643233/21500(CD)
Daga Commodities Private Limited: SEBI Reg. No. INZ000028833
Investor Grievances Email ID: compliance@dbonline.in & investors@dbonline.in
Copyright © 2016 All rights Reserved DB (International) Stock Brokers Ltd.     Designed, Developed and content powered by C-MOTS Infotech( ISO 9001:2015 certified )
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."         "Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors."          "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Attention Investors ::
subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries